Investors Seek Justice: Pomerantz Law Firm Investigates Neogen Corporation's Securities Practices

In a significant development for investors of Neogen Corporation, the Pomerantz Law Firm has launched an investigation into potential claims that could indicate the company was involved in unlawful business practices and securities fraud. The investigation arises amidst troubling news related to a product from Neogen that has been associated with severe adverse outcomes, including the fatalities of multiple horses.

A Troubling FDA Warning

On September 29, 2026, the U.S. Food and Drug Administration (FDA) made headlines when it issued a warning letter to Neogen. This warning came after the FDA linked a veterinary wound care product, Neogen Vet HYCOAT, to serious infections and multiple horse deaths. The FDA reported that this incident involved at least 20 horse fatalities, marking it as the largest death count tied to a flaw in an FDA-regulated veterinary medical product. The agency's findings indicated that there were significant concerns regarding microbiological contamination in a product that was labeled as sterile.

Following the FDA's announcement, Neogen initiated a voluntary recall of HYCOAT in late January 2026, but the damage had already been done to the company's reputation and financial standing. Investors learned the hard way about the risks associated with products that fail to meet safety standards.

Fallout from the Situation

As a direct result of this negative news, Neogen's stock experienced a sharp decline. On the same day the FDA's warning was made public, shares fell by $0.99, translating to a 7.22% drop, closing at $12.73 per share. This incident raised serious questions about the level of due diligence exercised by Neogen's leadership and whether they disclosed all pertinent information to shareholders in a timely manner.

Pomerantz's Role in Seeking Justice

The Pomerantz Law Firm, recognized for its prominent role in corporate and securities class action litigation, has made it clear that they are dedicated to protecting shareholders' rights. Founded over 85 years ago, the firm has a storied history of representing victims of securities fraud and corporate misconduct. Pomerantz's legal experts are currently investigating whether Neogen and its executives may have breached fiduciary duties or engaged in securities violations.

Investors who believe they may be affected by these developments are encouraged to reach out to Pomerantz for further information and to participate in the class action lawsuit. Danielle Peyton, an attorney at Pomerantz, can be contacted for inquiries at 646-581-9980, ext. 7980, or via email at [email protected].

Conclusion

As the Pomerantz Law Firm delves deeper into these claims, it highlights the importance of transparency and accountability in the corporate world, especially regarding the safety of consumer products. Investors must remain vigilant and informed of any threats to their investments, particularly when alarming FDA alerts and adverse product outcomes arise. This investigation into Neogen Corporation serves as a crucial reminder of the imperative for companies to uphold their responsibilities to both consumers and shareholders alike.